The WACC of Surgalign Holdings Inc (SRGA) is 5.9%.
Range | Selected | |
Cost of equity | 8.4% - 14.9% | 11.65% |
Tax rate | 1.6% - 1.8% | 1.7% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 5.4% - 6.3% | 5.9% |
Category | Low | High |
Long-term bond rate | 4.2% | 4.7% |
Equity market risk premium | 5.0% | 6.0% |
Adjusted beta | 0.84 | 1.62 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 8.4% | 14.9% |
Tax rate | 1.6% | 1.8% |
Debt/Equity ratio | 6.07 | 6.07 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 5.4% | 6.3% |
Selected WACC | 5.9% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
SRGA | Surgalign Holdings Inc | 6.07 | 2.7 | 0.39 |
CEMI | Chembio Diagnostics Inc | 1.12 | 1.86 | 0.88 |
EMDF | XL Rent Inc | 26.27 | -0.91 | -0.03 |
RVP | Retractable Technologies Inc | 0.07 | 0.55 | 0.52 |
SIEN | Sientra Inc | 26.62 | -1.12 | -0.04 |
TELA | TELA Bio Inc | 0.53 | 0.15 | 0.1 |
UEEC | United Health Products Inc | 0.04 | -0.65 | -0.62 |
UNVC | Univec Conglomerate Inc | 0.44 | 0.47 | 0.32 |
VYCO | Vycor Medical Inc | 0.22 | 0.93 | 0.77 |
XTNT | Xtant Medical Holdings Inc | 0.39 | 1.26 | 0.91 |
Low | High | |
Unlevered beta | 0.23 | 0.44 |
Relevered beta | 0.76 | 1.93 |
Adjusted relevered beta | 0.84 | 1.62 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for SRGA:
cost_of_equity (11.65%) = risk_free_rate (4.45%) + equity_risk_premium (5.50%) * adjusted_beta (0.84) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.